[Federal Register Volume 88, Number 79 (Tuesday, April 25, 2023)]
[Notices]
[Pages 25001-25002]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08637]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council on Drug Abuse.
    The meeting will be open to the public, as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
as well as those who need special assistance, such as sign language 
interpretation or other reasonable accommodations, should notify Dr. 
Gillian Acca via email at [email protected] five days in advance of 
the meeting. The open session will be videocast and can be accessed 
from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
    A portion of the meeting will be closed to the public in accordance 
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), 
Title 5 U.S.C., as amended. The grant applications and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: May 9, 2023.
    Closed: 10:30 a.m. to 11:45 a.m.
    Agenda: To review and evaluate grant applications.
    Open: 12:45 p.m. to 5:00 p.m.
    Agenda: Presentations and other business of the Council.
    Place: Rockledge II, Conference Room 270 A/B, National 
Institutes of Health, National Institute on Drug Abuse, 6701 
Rockledge Drive, Bethesda, MD 20892.
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown 
Street, Bethesda, MD 20852, 301-443-6480, [email protected].

    Any interested person may file written comments with the committee 
by forwarding the statement to Dr. Gillian Acca via email at 
[email protected]. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has procedures at https://www.nih.gov/about-nih/visitor-information/campus-access-security for 
entrance into on-campus and off-campus facilities. All visitor 
vehicles, including taxicabs, hotel, and airport shuttles will be 
inspected before being allowed on campus. Visitors attending a meeting 
on campus or at an off-campus federal facility will be asked to show 
one form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their visit.
    Additional Health and Safety Guidance: Before attending a meeting 
at an NIH facility, it is important that visitors review the NIH COVID-
19 Safety Plan at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/Pages/default.aspx for information about requirements and 
procedures for entering NIH facilities, especially when COVID-19 
community levels are medium or high. In addition, the Safer Federal 
Workforce website has FAQs for visitors at https://www.saferfederalworkforce.gov/faq/visitors/. Please note that if an 
individual has a COVID-19 diagnosis within 10 days of the meeting, that 
person must attend virtually. (For more information please read NIH's 
Requirements for Persons after Exposure at https://ors.od.nih.gov/sr/
dohs/safety/

[[Page 25002]]

NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/persons-after-
exposure.aspx and What Happens When Someone Tests Positive at https://ors.od.nih.gov/sr/dohs/safety/NIH-covid-19-safety-plan/COVID-assessment-testing/Pages/test-positive.aspx.) Anyone from the public 
can attend the open portion of the meeting virtually via the NIH 
Videocasting website (http://videocast.nih.gov). Please continue 
checking these websites, in addition to the committee website listed 
below, for the most up to date guidance as the meeting date approaches.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any 
additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: April 19, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-08637 Filed 4-24-23; 8:45 am]
BILLING CODE 4140-01-P